ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 13 Sep 2024
A- A+
Review of cancer drugs for prostate cancer Guidance is outdated and has been withdrawn on 13 Sep 2024.

Review of cancer drugs for prostate cancer (Withdrawn 13 Sep 2024) PES Treatments for advanced prostate cancer (Updated 19 Dec 2022)